Board Member
Verrica Pharmaceuticals Inc. (VRCA)Equibles does not estimate personal net worth.
Get an email with a short summary when Verrica Pharmaceuticals Inc. publishes a filing, an earnings call transcript or a press release.
Get VRCA alertsJayson Rieger is recorded as Board Member at Verrica Pharmaceuticals Inc. (VRCA) since November 5, 2024 and CEO at Verrica Pharmaceuticals Inc. (VRCA). The newest filing on record that lists Jayson Rieger as CEO at Verrica Pharmaceuticals Inc. (VRCA) is dated April 20, 2026. Verrica Pharmaceuticals Inc. reported in an 8-K filed November 4, 2024 that Jayson Rieger was appointed director, effective November 5, 2024. Verrica Pharmaceuticals Inc. reported in an 8-K filed November 4, 2024 that Jayson Rieger was appointed President and Chief Executive Officer, effective November 5, 2024. Verrica Pharmaceuticals Inc. reported in an 8-K filed November 4, 2024 that Jayson Rieger was appointed Chief Executive Officer. The proxy statement of Verrica Pharmaceuticals Inc. reports total compensation of $741,403 for Jayson Rieger in fiscal 2025, including a base salary of $300,000. Disclosed compensation is on record for 2 fiscal years. Jayson Rieger has spoken on 3 earnings calls across 1 company, most recently for Verrica Pharmaceuticals Inc. on November 14, 2025. Verrica Pharmaceuticals Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Verrica Pharmaceuticals Inc. includes Dr. Jayson Rieger (CEO and Board Member), John J. Kirby (CFO), John Kirby (CFO) and 7 others.
“the Company announced the appointments of Dr. Jayson Rieger as President and Chief Executive Officer and as a director, and John Kirby as interim Chief Financial Officer, effective November 5, 2024.”
“the Company announced the appointments of Dr. Jayson Rieger as President and Chief Executive Officer and as a director, and John Kirby as interim Chief Financial Officer, effective November 5, 2024.”
“In the third quarter, Verrica achieved multiple commercial, corporate, scientific and regulatory milestones, providing a strong foundation for future growth in YCANTH as well as significant upside potential for our late-stage pipeline.”
“Thank you, Kevin, and good evening, everyone, and thank you for joining us for our second quarter 2025 corporate update call. The second quarter featured a number of notable accomplishments across multiple areas of our business, each of which has made us stronger as a company.”
“And thank you for joining us for our fourth quarter and full year 2024 corporate update call.”
2024-11-05–present
Start not stated–present
Last confirmed April 20, 2026
Biotechnology · Healthcare
CEO, Board Member
2024-11-05–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Verrica Pharmaceuticals Inc. (VRCA) | President and Chief Executive Officer | $300,000 | $741,403 |
| 2024 | Verrica Pharmaceuticals Inc. (VRCA) | President and Chief Executive Officer | $47,727 | $1,236,225 |
